Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China

Fineline Cube Jun 3, 2026
Company Deals

Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market

Fineline Cube Jun 3, 2026
Company Deals

Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets

Fineline Cube Jun 2, 2026
Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China

Fineline Cube Jun 2, 2026
Company Deals

Servier Group Acquires Edgewise Therapeutics’ Muscular Dystrophy Business for Up to $2.65 Billion

Fineline Cube Jun 2, 2026
Policy / Regulatory

China’s NMPA Introduces Comprehensive Medical Device Classification Reforms with 2-5 Year Transitional Periods

Fineline Cube Jun 2, 2026
Company Drug

Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations

Fineline Cube Jun 3, 2026
Company Drug

Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World’s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule

Fineline Cube Jun 3, 2026
Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Fineline Cube Apr 4, 2026

Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong...

Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Fineline Cube Apr 4, 2026

Youcare Pharmaceutical Group (SHA: 688658) announced that its YKYY018 aerosolized inhalation formulation has received approval...

Others

Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline

Fineline Cube Apr 4, 2026

Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the...

Company Drug

Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen

Fineline Cube Apr 4, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) announced that the European Commission has granted marketing...

Company Drug

Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment

Fineline Cube Apr 4, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b/3...

Others

Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline

Fineline Cube Apr 4, 2026

Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253...

Company Drug

Bio-Thera Solutions Gains NMPA Clearance for Phase I/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors

Fineline Cube Apr 4, 2026

Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Deals

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

Fineline Cube Apr 3, 2026

Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply,...

Company Deals Digital

Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform

Fineline Cube Apr 3, 2026

Xellar Biosystems, a U.S.-based pioneer in “AI + organ-on-a-chip” technology, announced the successful completion of...

Company Deals

Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform

Fineline Cube Apr 3, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced an exclusive strategic partnership with TriNetX, Inc., granting Regeneron...

Company Drug

AstraZeneca’s Imfinzi-Imjudo Combo with Lenvatinib and TACE Shows Significant PFS Benefit in Early-Stage Liver Cancer, EMERALD-3 Trial Reveals

Fineline Cube Apr 3, 2026

AstraZeneca plc (NYSE: AZN) announced positive top-line results from the EMERALD-3 Phase III clinical trial,...

Company Drug

RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors

Fineline Cube Apr 2, 2026

RemeGen Ltd (HKG: 9995) announced it has received approval from China’s National Medical Products Administration...

Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Fineline Cube Apr 2, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced a strategic partnership with Sihuan...

Company Deals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

Fineline Cube Apr 2, 2026

Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive...

Company Drug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

Fineline Cube Apr 2, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received approval...

Company Drug

NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal

Fineline Cube Apr 2, 2026

China’s National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide...

Company Drug

Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers

Fineline Cube Apr 2, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced it has received approval from China’s National...

Company Deals Drug

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Apr 2, 2026

Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Amgen Inc. (NASDAQ: AMGN) announced a strategic collaboration...

Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026

China’s Center for Drug Evaluation (CDE) has published the 105th batch of reference preparations for...

Company Drug

Eli Lilly Secures FDA Approval for Foundayo (Orforglipron) in Obesity Treatment, Shipments Begin April 6

Fineline Cube Apr 2, 2026

Eli Lilly and Company (NYSE: LLY) announced it has received marketing approval from the US...

Posts pagination

1 … 31 32 33 … 677

Recent updates

  • Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China
  • Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations
  • Genesis MedTech Secures CE Mark for World’s First Integrated Scissor-Type Ultrasonic Scalpel, Following 2025 China Approval
  • Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market
  • Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World’s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China

Company Drug

Huahai Pharmaceutical Receives NMPA Approval for Dual-Target IPF Therapy HB0056, Adding to Global Clinical Trial Authorizations

Company Medical Device

Genesis MedTech Secures CE Mark for World’s First Integrated Scissor-Type Ultrasonic Scalpel, Following 2025 China Approval

Company Deals

Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.